Analysts expect that Flexion Therapeutics Inc (NASDAQ:FLXN) will report $14.03 million in sales for the current quarter, according to Zacks. Three analysts have made estimates for Flexion Therapeutics’ earnings. The lowest sales estimate is $12.60 million and the highest is $15.50 million. Flexion Therapeutics posted sales of $3.80 million in the same quarter last year, which suggests a positive year over year growth rate of 269.2%. The business is expected to announce its next earnings results on Tuesday, August 6th.

On average, analysts expect that Flexion Therapeutics will report full year sales of $66.45 million for the current year, with estimates ranging from $61.50 million to $70.80 million. For the next financial year, analysts forecast that the business will report sales of $142.30 million, with estimates ranging from $127.60 million to $169.30 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Flexion Therapeutics.

Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings data on Wednesday, May 8th. The specialty pharmaceutical company reported ($1.09) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.13) by $0.04. The business had revenue of $10.56 million during the quarter, compared to analyst estimates of $11.10 million. Flexion Therapeutics had a negative return on equity of 131.94% and a negative net margin of 549.07%.

Several analysts have recently weighed in on FLXN shares. Benchmark upgraded Flexion Therapeutics from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a report on Thursday, May 9th. BidaskClub lowered Flexion Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, March 7th. Laidlaw set a $18.00 price objective on Flexion Therapeutics and gave the company a “buy” rating in a report on Thursday, April 11th. Zacks Investment Research raised Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, February 6th. Finally, Northland Securities reaffirmed a “buy” rating and set a $20.00 target price on shares of Flexion Therapeutics in a report on Friday, March 1st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the stock. Flexion Therapeutics has an average rating of “Buy” and a consensus target price of $23.71.

Shares of Flexion Therapeutics stock traded up $0.22 during trading on Tuesday, hitting $12.74. The stock had a trading volume of 570,164 shares, compared to its average volume of 663,964. The company has a quick ratio of 6.06, a current ratio of 6.32 and a debt-to-equity ratio of 2.10. The firm has a market cap of $484.03 million, a price-to-earnings ratio of -2.84 and a beta of 1.56. Flexion Therapeutics has a fifty-two week low of $9.65 and a fifty-two week high of $29.10.

In related news, insider Michael D. Clayman bought 4,046 shares of Flexion Therapeutics stock in a transaction dated Tuesday, March 12th. The stock was acquired at an average cost of $12.36 per share, with a total value of $50,008.56. Following the completion of the acquisition, the insider now directly owns 70,856 shares in the company, valued at approximately $875,780.16. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Michael D. Clayman bought 4,012 shares of Flexion Therapeutics stock in a transaction dated Friday, May 10th. The shares were bought at an average cost of $12.48 per share, with a total value of $50,069.76. Following the completion of the acquisition, the insider now owns 74,868 shares of the company’s stock, valued at $934,352.64. The disclosure for this purchase can be found here. Over the last ninety days, insiders have bought 20,058 shares of company stock valued at $249,158. 16.01% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in FLXN. Next Capital Management LLC purchased a new stake in Flexion Therapeutics in the 4th quarter worth about $84,000. BNP Paribas Arbitrage SA lifted its stake in Flexion Therapeutics by 53,692.3% in the 1st quarter. BNP Paribas Arbitrage SA now owns 6,993 shares of the specialty pharmaceutical company’s stock worth $87,000 after acquiring an additional 6,980 shares in the last quarter. Advisor Group Inc. lifted its stake in Flexion Therapeutics by 68.2% in the 4th quarter. Advisor Group Inc. now owns 8,608 shares of the specialty pharmaceutical company’s stock worth $97,000 after acquiring an additional 3,490 shares in the last quarter. Metropolitan Life Insurance Co. NY lifted its stake in Flexion Therapeutics by 341.0% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 10,455 shares of the specialty pharmaceutical company’s stock worth $118,000 after acquiring an additional 8,084 shares in the last quarter. Finally, Royce & Associates LP purchased a new stake in Flexion Therapeutics in the 1st quarter worth about $187,000. 91.47% of the stock is owned by hedge funds and other institutional investors.

About Flexion Therapeutics

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.

Read More: What are earnings reports?

Get a free copy of the Zacks research report on Flexion Therapeutics (FLXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.